This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Dronabinol Interactions With Cognitive Enhancing Drug in Humans

This study has been completed.
Sponsor:
Collaborators:
VA Office of Research and Development
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Mehmet Sofuoglu, Yale University
ClinicalTrials.gov Identifier:
NCT00842985
First received: February 11, 2009
Last updated: April 21, 2017
Last verified: April 2017
Results First Received: August 5, 2011  
Study Type: Interventional
Study Design: Intervention Model: Sequential Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Cannabis
Marijuana Abuse
Intervention: Drug: drug condition

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
All Participants

There were 4 sessions given in a counterbalanced order: Dronabinol+Modafinil, Dronabinol+Placebo, Placebo+Modafinil, Placebo+Placebo.

Not all participants received the interventions in the same order.


Participant Flow for 8 periods

Period 1:   Screening
    All Participants
STARTED   53 
COMPLETED   26 
NOT COMPLETED   27 
Did not meet entrance requirements                27 

Period 2:   First Intervention
    All Participants
STARTED   26 [1] 
COMPLETED   20 [2] 
NOT COMPLETED   6 
Withdrawal by Subject                3 
Protocol Violation                3 
[1] Signed Consent
[2] Completed 1st Intervention

Period 3:   Washout Period of GE 4 Days
    All Participants
STARTED   20 
COMPLETED   18 
NOT COMPLETED   2 
Withdrawal by Subject                2 

Period 4:   Second Intervention
    All Participants
STARTED   18 
COMPLETED   17 
NOT COMPLETED   1 

Period 5:   Washout Period of GE 4 Days
    All Participants
STARTED   17 
COMPLETED   15 
NOT COMPLETED   2 
Withdrawal by Subject                2 

Period 6:   Third Intervention
    All Participants
STARTED   15 
COMPLETED   15 
NOT COMPLETED   0 

Period 7:   Washout Period of GE 4 Days
    All Participants
STARTED   15 
COMPLETED   15 
NOT COMPLETED   0 

Period 8:   Fourth Intervention
    All Participants
STARTED   15 
COMPLETED   15 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
All Participants

There were 4 sessions given in a counterbalanced order: Dronabinol+Modafinil, Dronabinol+Placebo, Placebo+Modafinil, Placebo+Placebo.

Not all participants received the interventions in the same order.


Baseline Measures
   All Participants 
Overall Participants Analyzed 
[Units: Participants]
 53 
Age 
[Units: Participants]
Count of Participants
 
<=18 years      0   0.0% 
Between 18 and 65 years      53 100.0% 
>=65 years      0   0.0% 
Age 
[Units: Years]
Mean (Standard Deviation)
 33.7  (7.7) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      11  20.8% 
Male      42  79.2% 
Region of Enrollment 
[Units: Participants]
 
United States   53 


  Outcome Measures

1.  Primary:   CANTAB:CAmbridge Neuropsychological Test Automated Battery RVIP: Rapid Visual Information Processing   [ Time Frame: Once for each test session (4 total). ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data

One dose of modafinil Brief treatment duration and use of a low dose of THC Cognitive testing assessed only two tasks. Outcome measures were limited by small sample size.

Limited generalizability because heavy cannibas users were excluded



  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Mehmet Sofuoglu, M.D., Ph.D.
Organization: Yale University
phone: 203-937-4809
e-mail: mehmet.sofuoglu@yale.edu


Publications of Results:

Responsible Party: Mehmet Sofuoglu, Yale University
ClinicalTrials.gov Identifier: NCT00842985     History of Changes
Other Study ID Numbers: 0702002357
MIRECC 00000000 ( Registry Identifier: Veteran's Administration )
P50DA009241 ( U.S. NIH Grant/Contract )
Study First Received: February 11, 2009
Results First Received: August 5, 2011
Last Updated: April 21, 2017